Sigmoid Pharma Limited is a specialty pharma company headquartered in Dublin, Ireland Sigmoid’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases and disorders. Sigmoid achieves its goal by applying its proprietary SmPill® oral drug delivery technology and pharmacological expertise to approved drugs or new chemical or biological entities.Sigmoid is led by lead inventor and founder, Dr.

Founded in 2009, Strōma Medical Corporation is a late-stage research and development company located in Laguna Beach, CA. Inventor/scientist Gregg Homer, JSD (PhD) developed and patented a non-invasive procedure to change eye color from brown to blue.  It is our intent that the procedure will be performed in the doctor's office with only a topical anesthetic and will take less than 20 seconds to complete. The permanent eye color change will occur gradually over the following two to four weeks and our clinical studies are designed to confirm these results.

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection.  Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting.  We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies.  Our plan and succes

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues.

The goal is to grow Portage by carefully selecting compelling products to license, acquire or position as a joint venture. The product portfolio will be carefully selected to be at various stages in drug development but with an overriding characteristic of being attractive to large pharmaceutical companies. Portage has a strong team with extensive experience in drug development that will be leveraged to source the aforementioned products, to undertake the due diligence and guide them through drug development to monetization.

The investment objective of the Fund is to seek growing income distributions with capital appreciation potential in the long term by investing in a diversified portfolio of Biopharma Sector Securities. The Fund's portfolio is largely composed of high-quality pharmaceutical names with fortress-like balance sheets, a solid dividend payout and some growth options. At the same time the portfolio has a significant allocation to well-funded innovative smaller companies, often in the biotechnology space, with advanced pipelines of highly promising and innovative therapeutics.

Mann Bioinvest is an expert in the biopharma sector. Based in the Isle of Man, the company was established to service sophisticated clients seeking advice on the biopharma sector. Founded in 2012 by renowned investor and entrepreneur Jim Mellon, Mann Bioinvest provides independent portfolio construction advice based on rigorous analysis of opportunities in the biopharma sector.

Miraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs.  Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians. 

Port Erin is a new company incorporated on 3 May 2011 under the law of the Isle of Man for the purpose of investing in the biotechnology and biopharmaceutical sector.The Company's strategy is to create value for Shareholders through investing in companies that have the potential to generate substantial revenues through the development of biopharmaceutical drugs.The Company's Non-Executive Chairman is James Mellon, who has had a successful career in the fund management industry.The Company intends to co-invest wherever possible alongside Mr Mellon in investments that he has identified.The Di

Plethora Solutions (AIM: PLE) is a speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.